Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could your heartburn meds cause gut bacteria overgrowth? new study investigates

NCT ID NCT05976165

Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at whether people who take proton pump inhibitors (PPIs) for heartburn or acid reflux develop an overgrowth of bacteria in the small intestine. Researchers will use a simple breath test to check for this condition. The goal is to learn how common this problem is and how it relates to symptoms like bloating.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Breath testing (carbohydrate solution)
What this could lead to
If successful, this could help doctors understand whether PPIs raise the risk of SIBO and guide better management of heartburn.
What could go wrong
This is a small, early observational study with only 50 participants, so results may not apply to everyone. Breath testing is not a direct treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Predominant symptoms of gastroesophageal reflux disease including heartburn, regurgitation * Subjects must be able to give appropriate informed consent Exclusion criteria: * Prior diagnosis of SIBO * Use of PPIs or H2R-anatagonstists in the prior 3 months * Major concomitant illness (renal, hepatic, rheumatologic or cardiovascular disease, or malignancy) * Antibiotic therapy within one month * Prior gastrointestinal surgery including esophageal, gastric, and small or large bowel surgery * Previously diagnosed irritable bowel syndrome or inflammatory bowel disease * Individuals who are pregnant or breast feeding * Patients with plans to become pregnant * Inability to take PPIs, including allergy/sensitivity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroesophageal reflux are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease Heartburn

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastroesophageal reflux Heartburn Regurgitation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mayo Clinic Florida

    RECRUITING

    Jacksonville, Florida, 32224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.